

Three Unique Dual-Pathway Biologics, Clinically Validated for Therapeutic Areas with Unmet Needs

October 2024

Nasdaq Ticker: ZURA

Forward Looking Statements Disclaimer

This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believe," "predict," "potential," "continue," "strategy," "future," "opportunity," "would," "seek," "outlook" and the negatives of such terms and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These forward-looking statements may include, but are not limited to: expectations with respect to development and regulatory plans, trial designs, and the costs, timing and results thereof, expectations with respect to milestones and key events, including the timing of study initiation and completion; expectations with respect to Zura Bio's development program, including clinical trials and the timing thereof, and expectations with respect to development programs, data readouts and product candidates of other parties; Zura Bio's cash resources and projected cash runway; the potential to raise additional capital to support the company's operations; the potential of pipeline assets to offer broader and improved clinical responses; expectations with respect to addressable markets, projected CAGRs and patient populations; and expectations with respect to the use of proceeds from any financing transactions. These statements are based on various assumptions, whether or not identified in this communication. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, a prediction or a definitive statement of

Actual events are difficult or impossible to predict and could differ materially from those expressed or implied in such forward-looking statements, as a result of these risks and uncertainties, which include, but are not limited to: the potential of Zura Bio's product candidates and their related benefits, competing product candidates and products both in development and approved; Zura Bio's vision and strategy; the timing of key events and initiation of Zura Bio's studies and relate benefits, competing product candidates and products both in development and approved; Zura Bio's vision and strategy; the timing or key events and initiation of Zura Bio's studies and relase of clinical data may take longer than anticipated or may not be achieved at all; the potential general acceptability and maintenance of Zura Bio's additional financing may not be achieved; Zura Bio has not completed any clinical trials, and has no products approved for commercial sale; Zura Bio has incurred significant losses since inception, and expects to incur significant losses for the foreseeable future and may not be achieve or sustain profitability in the future; Zura Bio requires substantial additional capital to finance its operations, and jet is unable to raise such capital when needed or on acceptable terms, Zura Bio relies on third-party contract development manufacturing organizations of the manufacture of clinical maralis; Zura Bio may be unable to renew existing contracts or enter into new contracts; Zura Bio may be unable to successfully respond to general economic and geopolitical conditions; Zura Bio may be unable to adequately protect its intellectual property rights; and other factors set forth in documents filed, or to be filed by Zura Bio, with the SEC, including the risks and uncertainties described in the "Risk Factors" section of Zura Bio's Annual Report on Form 10-K for the year ended December 31, 2023 and other filings with the SEC. These risks and uncertainties may be amplified by health epidemics or other unanticip

Zura Bio does not undertake or accept any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, or should circumstances change, except as otherwise required by securities and other applicable laws.

This presentation discusses product candidates that are under clinical study, and which have not yet been approved for marketing by the US Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. Caution should be exercised when comparing data across trials of different products and product candidates. Differences existing between trial designs and patient populations and characteristics. The results across such trials may not have interpretative value on Zura Bio's existing or future results. Statements included herein concerning clinical trials for the product candidates have not been reviewed or endorsed by Eli Lilly ("Lilly") or Pfizer.


This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

zurabio

Company Summary



High-Potential Biologics:	Three novel, clinically validated [*] dual-pathway biologics, each targeting multi-billion-dollar markets, advancing towards Phase 2 trials
Lead Asset Development:	Tibulizumab Phase 2 study for SSc expected to commence in 4Q 2024, with a subsequent trial for HS anticipated in 2Q 2025
Strategic Milestones:	Anticipating 2 key internal catalysts and up to 11 external readouts over the next 36 months, with potential to significantly drive value creation
Proven Leadership:	An experienced team with a demonstrated history of driving over \$8 billion in mergers and acquisitions within the last three years, showcasing their ability to execute strategic growth and value creation
Financial Strength:	Cash runway to support operations as currently planned through 2027



Sources: Zura Bio Press Releases and Filings

Acronyms: HS, hidradenitis suppurativa; Q, quarter; SAB, scientific advisory board; SSc, systemic sclerosis

Pipeline of Novel Dual-Pathway Biology Designed to Meaningfully Advance Outcomes in I&I Diseases



			Nasdaq:
		Phase 1	Phase 2
tibulizumab Pipeline-in a-product	tabalumab Anti-Baff Ab Only bispecific antibody targe IL-17A and BAF	eting – n=57 single dose	Planning to initiate Phase 2 studies of tibulizumab for SSc in 4Q 2024 and for HS in 2Q 2025.
crebankitug Potential best-in-class	L-7R and TSLP Inhibition with potential best in class TSLP inhibition	✓ 93 participants dosed	Actively assessing the competitive landscape and evaluating potential therapeutic indications to guide our future development efforts.
torudokimab Potential best-in-class	Epithelial Damage	 ✓ 244 participants dosed – n= 81 single dose 	Actively assessing the competitive landscape and evaluating potential therapeutic indications to guide our future development efforts.

(*) Phase 1/1b studies conducted by Eli Lilly & Co. (Phase 1 SAD in participants with rheumatoid arthritis, Phase 1b MAD in participants with Sjogren's syndrome, Phase 1 SAD in healthy Japanese and Caucasian participants)

(**) Phase 1/lb studies conducted by Pfizer. (Phase 1a SAD in healthy adult volunteers, Phase 1b MAD in participants with type-1 diabetes, Phase 1b MAD in participants with multiple sclerosis)

(***) Phase 1/2 studies conducted by Eli Lilly & Co. (Phase 1 SAD, MAD and Safety / PK in in healthy participants, Phase 2 in participants with atopic dermatitis)

Sources: Clinical Study Reports

Acronyms: BAFF, B cell-activating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HS, hidradenitis suppurativa; I&I, inflammation and immunology; IL, interleukin; Q, quarter; SSc, systemic sclerosis; TSLP, thymic stromal lymphopoietin

Dual-Biology Pathways Present Opportunities for High-Impact Therapeutic Targets with Attractive Market Potential



Nasdaq: ZURA

Prevalence ¹ U.S., EU5* and Japan	Potential Therapeutic Area	TAM (\$USD) U.S., EU5* and Japan
270 k	SSc systemic sclerosis	\$2,500 M
700 k	HS hidradenitis suppurativa	\$3,200 M
7 M	AA alopecia areata	\$5,200 M
32 M	COPD chronic obstructive pulmonary disease	\$23,692 M
25 M	AD atopic dermatitis	\$31,000 M
47 M	Asthma	\$25,247 M
~112 M		\$90,839 M

(*) Germany, France, Italy, Spain, and United Kingdom

Sources: ¹ Clarivate/DRG. Accessed 19 August 2024. Projected Prevalence and TAM 2032; "Alopecia Areata - National Alopecia Areata Foundation." NAAF, <u>www.naaf.org/alopecia-areata</u>; Internal Analysis; Evaluate Pharma

Acronyms: k, kilo-thousand; M, million; TAM, total addressable market

Zura is Led by a Strong Leadership Team with a Proven Track Record in Drug and Business Development




Nasdaq: ZURA



Key Anticipated Events Through 2026



Nasdaq: ZURA



(*) Other IL-7Ra clinical data sources that may be available include a Phase 2 trial of lusvertikimab in ulcerative colitis.

Sources: ¹Zura Planning Assumptions; ²clinicaltrials.gov; Company Presentations

Acronyms: AA, alopecia areata; AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; HS, hidradenitis suppurativa; IL, interleukin; Q, quarter; SSc, systemic sclerosis; TSLP, thymic stromal lymphopoietin

★ tibulizumab

ZB-106 Anti-BAFF + IL-17

> Tibulizumab, is a humanized bispecific dual antagonist antibody, and has been engineered to bind to and neutralize both BAFF and IL-17A. Our approach with tibulizumab is to inhibit both pathways with a single agent, potentially providing clinical benefits to a broader range of patients, as well as a greater level of effect.

systemic sclerosis (SSc)

Rationale for Phase 2 Study in Systemic Sclerosis Patients



TAM projected to exceed \$2B



Increased Probability of Success Through Scientific and Clinical Validation

- IL-17 and BAFF are both validated as key contributors to SSc progression
- Multiple clinical studies demonstrate that inhibiting IL-17 and targeting B cells benefits SSc treatment
- Simultaneously inhibiting these validated targets may improve outcomes



High Unmet Need and Significant Value

- Rare and life-threatening condition with a 40%-60% mortality rate within 10 years
- Limited treatment options available, with no advanced-line agents approved specifically for SSc
- 96% of rheumatologists identify SSc as the highest area of patient need ¹

Systemic Sclerosis is a Multi-Organ Disease with No Effective Treatments



tibulizumab | ZB-106

Systemic sclerosis is a rare & life-threatening disease

~300,000

people with SSc in US, EU and Japan¹

Zero

SSc-specific * drugs approved

(*) no effective treatment exists that combats the disease across organ systems

Systemic sclerosis is characterized by tissue inflammation and fibrosis




Multiple areas for evaluation and improvement in SSc



Rheumatologists Rank SSc as the Highest Area of Need, with Significant Opportunity for Greater and Broader Clinical Benefit



tibulizumab | ZB-106



96% of respondents highlight a pressing need for new pharmacological treatments in SSc

Both IL-17A and BAFF-Mediated Inflammation Contribute to SSc Progression



tibulizumab | ZB-106

Selective antibody therapy may be insufficient to address the heterogeneity of SSc

BAFF

IL-17A is a pro-inflammatory cytokine that has been identified as a key contributor to SSc progression.

- IL-17A is increased in skin lesions and peripheral blood^{1,2}
- Neutralization of IL-17A protected against bleomycin induced fibrosis³

IL-17A

Binds to BAFF trimer and BAFF 60-mer Binds to IL-17A preventing IL-A/A Preventing binding to BAFF-R. TACI. and and IL-17A/F heterodimerization¹ BCMA² BAFF BAFF APRIL Trimer Trimer 60-mer IL-17A / IL-17F IL-17F / IL-17F IL-17A / IL-17A IL-17RC BAFF-R BCMA IL-17RA TACI Immature T Cell independent Antibody Plasma Cell B-Cell Responses / Survival Autoimmune Survival B Cells Regulation / Inflammation and Class switch recombination Maturation

B cell activating factor (BAFF) is a potent B-cell activator and promotes the survival and differentiation of B-cells.

- BAFF is increased in peripheral blood and correlates with skin fibrosis and incidence of pulmonary fibrosis^{4,5}
- In pre-clinical models BAFF blockade prevents skin fibrosis & autoantibody production^{6,7}


Inhibiting both IL-17A and BAFF may lead to better clinical outcomes in SSc

Sources: ¹Zhou, Q., et al. The Journal of Immunology, doi:10.4049/jimmunol.1500956; ²Yang, X., et al. Arthritis Research & Therapy, doi:10.1186/ar4430; ³Cipolla, E., et al. The FASEB Journal, doi:10.1096/fj.201700289r; ⁴ Matsushita, T. Arthritis & Rheumatism, doi:10.1002/art.21526; ⁵ Matsushita et al. J Rheum 2007; ⁶ Matsushita et al. J Invest Dermatol 2007; ⁷ François, A., et al. Journal of Autoimmunity, doi:10.1016/j.jaut.2014.08.003.

©2024 Zura Bio Ltd. **12**


Tibulizumab Was 'designed and engineered' to Enable Engagement with IL-17A, BAFF, or <u>Both Simultaneously</u>





Tibulizumab Targets IL-17A, BAFF, or Both Simultaneously


Tibulizumab uniquely targets BAFF for B cell regulation and IL-17A for inflammation control, offering a comprehensive approach to treating autoimmune and inflammatory diseases.



Pre-Clinical Evidence of Additive Benefit from Inhibiting IL-17A and Neutralizing BAFF



tibulizumab | ZB-106



Rheumatoid arthritis is a prototypic autoimmune disease where individually targeting **IL-17A-mediated inflammation or depleting B cells** has been clinically validated

The collagen-induced arthritis (CIA) murine model is similarly characterized by **increased IL-17A production and B cells** that drive disease pathogenesis

Surrogate murine antibodies were used to evaluate whether **neutralization of IL-17A and BAFF** was superior to targeting individual pathways

Mice were injected with **anti-IL-17A and/or anti-BAFF** on days 22, 29, and 36

Blockade of both IL-17A and BAFF was associated with reduced:

- Disease severity
- Anti-collagen antibodies
- Inflammation in the hind paw (histology score)

Separately Inhibiting IL-17A or BAFF Has Demonstrated Efficacy in SSc Placebo-Controlled Studies



tibulizumab | ZB-106

IL-17 receptor antagonist – Phase 3

Brodalumab


- Achieved primary and endpoints for skin (reduced mRSS) and lung (improved FVC), respectively.¹
- Demonstrated therapeutic effects on lung/respiratory functions, digital ulcers, symptoms of gastroesophageal reflux disease, and QOL without noteworthy safety concerns

CLINICAL PRECEDENT

BAFF antagonist – IIT


Belimumab

- A 52-week, investigator-initiated, single-center, double-blind, placebocontrolled pilot study in 20 participants with dcSSc on MMF²
- Both treatment groups experienced improvements in mRSS, favoring belimumab (-10 vs. -3; p = NS)
- Secondary endpoints were met with statistical significance in two endpoints: SHAQ-DI and VAS Raynaud's phenomenon



CLINICAL PRECEDENT





Sources: ¹ Fukasawa, T., et al. Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2022-eular.2519. ² Gordon, Jessica K., et al. Arthritis Rheumatology, doi:10.1002/art.40358. Acronyms: BAFF, B cell-activating factor; dcSSc, diffuse cutaneous systemic sclerosis; FVC, forced vital capacity; IIT, investigator-initiated trial; MMF, mycophenolate mofetil; mRSS, modified Rodnan Skin Score; QOL, quality of life; SHAQ-DI, scleroderma health assessment questionnaire – disability index; SSc, systemic sclerosis; VAS, visual analogue scale

Planned Phase 2 SSc Study^{*} is Focused on Demonstrating Benefit in Skin and Lung Endpoints




tibulizumab | ZB-106

KEY INCLUSION CRITERIA

- Early diffuse cutaneous SSc, enriched for SSc-ILD
- Stable background therapy
- Anti-centromere antibody negative

- Disease duration ≤2 years: mRSS 15-45
- Disease duration 2-5 years:
 - mRSS 20-45
 - RNA Pol III negative, or evidence of recent progression





(*) Study design is subject to change.

Sources: Zura Internal Planning

Acronyms: CRISS, Composite Response Index in Systemic Sclerosis; FVC, forced vital capacity; HAQ-DI, health assessment questionnaire – disability index; ILD, interstitial lung disease; mRSS, modified Rodnan skin score; OLE, open-label extension; qHRCT, quantitative high-resolution computed tomography; SSc, systemic sclerosis

modified Rodnan Skin Score (mRSS): Endpoint for Assessing Skin Thickness and Fibrosis




tibulizumab | ZB-106



Severe skin thickening and tightening restricts movement and causes painful ulcers on the hands and fingers, significantly impairing daily activities and quality of life. The **mRSS assesses skin thickness** in systemic sclerosis patients by **evaluating 17 body sites** (e.g., face, chest, abdomen, arms, legs). Each site is scored from 0 to 3.


The total score ranges from 0 to 51, with **higher scores** indicating greater skin involvement.



In Phase 2, Lung Involvement using qHRCT will be a Key Secondary Endpoint



tibulizumab | ZB-106




ILD includes various pulmonary disorders marked by inflammation and progressive lung fibrosis, resulting in restrictive lung function and impaired gas exchange.

SSc often leads to ILD due to immune system dysregulation and subsequent lung interstitial fibrosis.

QILD by HRCT provides a sensitive measure of lung involvement, detecting changes as small as 2%.

Example of improvement after 24 months of MMF in total lung involvement



The blue and red areas show QLF, while the yellow area shows quantitative ground glass. The entire colored area represents QILD. After 24 months, QLF areas decreased (*arrow in B*).

Sources: Goldin, J., et al. Annals of the American Thoracic Society, doi:10.1513/annalsats.201802-079oc; Zura Bio internal planning Acronyms: ILD, interstitial lung disease; MMF, mycophenolate mofetil; qHRCT, quantitative high-resolution computed tomography; QILD, quantitative interstitial lung disease; QLF, Quantitative Lung Fibrosis; SSc, systemic sclerosis

External Development Programs^{*}: *Key Studies and Marketed SSc-ILD Specific Products for Systemic Sclerosis*



As of September 2024. Does not include trials only conducted in Japan Studies on clinicaltrials.gov where the primary condition listed is systemic sclerosis (diffuse or limited cutaneous) Studies on clinicaltrials.gov with the condition listed is systemic sclerosis with interstitial lung disease

(*)

(**) (***) zurabio

Revised CRISS Endpoint in SSc Assessment




- tibulizumab | ZB-106

STEP 1: Assess for significant SSc-related events:

If no significant SSc-related event, proceed to Step 2 **STEP 2:** Assess each core measure for improvement / worsening:

- New scleroderma renal crisis
- New decline in percent predicted FVC≥15% in established ILD or new percent predicted FVC below 80% predicted
- New onset of left ventricular failure requiring treatment
- New onset of pulmonary arterial hypertension requiring treatment
- Gastrointestinal dysmotility requiring enteral or parenteral nutrition
- Digital ischemia with gangrene, amputation, or hospitalization requiring treatment



RESPONDER: Improvement in ≥2 core measures with worsening in ≤1 core measure

Sources: Zura Internal Planning

Acronyms: CGA, clinical global assessment; CRISS: composite response index in systemic sclerosis; FVC, forced vital capacity; HAQ-DI, health assessment questionnaire – disability index; ILD, interstitial lung disease; mRSS, modified Rodnan skin score; PtGA, patient global assessment

Phase 2 SSc Development Aims to Reduce Historical Risks in Therapeutic Area Development





Historic Drivers of SSc Study Failures:

- Novel and unvalidated mechanisms
- Inclusion/exclusion criteria oversights
- Challenges in balancing sample sizes for mRSS and ILD participants



Increasing Probability of Success:

- Larger study sample size increases the probability of success (mRSS)
- High-resolution CT highly correlates with FVC, improving ILD readthrough
- Sufficient sample size for ILD readouts to understand potential Phase 3 effects

📌 tibulizumab

ZB-106 Anti-BAFF + IL-17

> Tibulizumab, is a humanized bispecific dual antagonist antibody, and has been engineered to bind to and neutralize both BAFF and IL-17A. Our approach with tibulizumab is to inhibit both pathways with a single agent, potentially providing clinical benefits to a broader range of patients, as well as a greater level of effect.

hidradenitis suppurativa (HS)

Rationale for Phase 2 Study in Hidradenitis Suppurativa Patients





Increased Probability of Success Through Scientific and Clinical Validation

- IL-17A and BAFF are clinically validated as key contributors to HS pathology
- Inhibiting IL-17A or disrupting B cells individually shows strong clinical support
- Ixekizumab shows high affinity for IL-17A and IL-17A/F
- Dual inhibition of these targets could improve patient outcomes



Unmet Need and Growth Potential

- 50% to 70% of HS patients do not achieve HiSCR75 with current treatments
- In the chronic phase, BAFF may play a more significant role, highlighting an unmet need that tibulizumab can address
- The TAM is projected to grow to \$3.5B \$4B by 2030

©2024 Zura Bio Ltd. 24

An Overview of Hidradenitis Suppurativa





DISEASE OVERVIEW

- Hidradenitis suppurativa is an inflammatory follicular skin disease
- Skin lesions form in the armpits, groin, and under the breasts due to inflammation and infection of the sweat glands
- ✓ Recurrent nodules and abscesses resulting in pus-like discharge
- ✓ Difficult-to-heal open wounds and scarring
- ✓ Increased Th1/Th17 and B cell mediated inflammation ¹⁻³
- ✓ Disproportionately affects women between adolescent age to 55 years of age ^{4, 5}





CLINICAL OPPORTUNITY ⁶

~300K people living with HS in the U.S.

Average time to diagnosis is **7 years**

~>50% patients still left inadequately treated

Sources: ¹Moran, Barry, et al. Journal of Investigative Dermatology, doi:10.1016/j.jid.2017.05.033. ²Banerjee, Anirban, et al. Immunological Investigations, doi:10.1080/08820139.2016.1230867. ³ Sabat, Robert, et al. Journal of Allergy and Clinical Immunology, doi:10.1016/j.jaci.2022.10.034. ⁴Garg, Amit, et al. JAMA Dermatology, doi:10.1001/jamadermatol.2017.0201. ⁵Ingram, John R. British Journal of Dermatology, doi:10.1111/bjd.19435. ⁶ Medical Literature, MEDACorp KOL Discussions


B Cell Signaling Potentiates HS Disease


💎 zurabio

tibulizumab | ZB-106

Elevated **CD20+** B cells and **CD138+** plasma cells in chronic HS lesions sustain inflammation. ^{2,3}

Increased BAFF in HS lesions promotes B cell activation and inflammation.^{2,3}





Reducing BAFF in HS lesions decreases B cell and plasma cell gene expression, indicating a potential therapeutic approach. ^{1,4}

Overlapping expression of **CD20+** and **BAFF**. ^{1,4}

Sources: ¹Van der Zee, H.H., et al. British Journal of Dermatology, doi:10.1111/j.1365-2133.2011.10698.x.² Rumberger, Beth E., et al. Inflammation Research, doi:10.1007/s00011-020-01381-7. ³Sabat, Robert, et al. Journal of Allergy and Clinical Immunology, doi:10.1016/j.jaci.2022.10.034. ⁴Gudjonsson, Johann E., et al. JCl Insight, doi:10.1172/jci.insight.139930

Role of IL-17A and B Cells Is Clinically Validated;

However, Clinical Effect Remains Modest with Single-Pathway Inhibition

zurabio

tibulizumab | ZB-106

		U NOVARTIS			O MoonLake
company and drug INN >>		secukinumab	remibrutinib*	bimekizumab	sonelokimab
Мес	hanism	IL-17 A	BTKi	IL-17 A/F	IL-17 A/F
Administration		SC/IV	PO	SC	SC
Phase		Phase 3	Phase 2b	Phase 2	Phase 2
Dosing		30mg Q2W for 16W	100 mg or 25 mg BID	320mg Q2W for 12W	120mg Q2W for 12W
Total Patients		n = 360	n = 77	n = 88	n = 234
Efficacy (HiSCR50)	Non-Placebo Adjusted	42% - 45%	48.5% - 72.7%	63%	66%
	Placebo Adjusted	11% +	38%	35%	38%
Efficacy	Non-Placebo Adjusted	N/A	27.3% - 42.4%	50%	43%
(HiSCR75)	Placebo Adjusted	N/A	24%	29%	29%
Safety	Candidiasis	0% - 3% ¹	0	9%	10.5%

There have been no head-to-head clinical trials between the product candidates listed above. Study designs and protocols for each product candidate were different, and as a result, results (*) may not be comparable between product candidates.

Sources: Company Presentations, Publications and Research.

¹Represents data from psoriasis trial. ²Represents safety data from psoriatic arthritis trial remibrutinib, 2024 AAD S026.

Represents data from psonasis trai. - Represents safety data from psonasis trai. - Representation safety data f IV, intravenous; PO, per os or by mouth; Q2W, every two weeks; Q4W, every four weeks; SC, subcutaneous

Tibulizumab^{*} IL-17A Component Has Class-Leading Binding Affinity Against IL-17A and IL-17A/F



tibulizumab | ZB-106

Ixekizumab is a humanized IgG4 monoclonal antibody



- Binding affinity, quantified by the dissociation constant (K_D), reflects the strength of interaction between a drug and its target, with a lower K_D indicating stronger binding.
- Stronger binding affinity ensures effective neutralization of the target, leading to the potential for improved clinical outcomes.


(*) Tibulizumab was engineered from Taltz® (ixekizumab)

Sources: ¹Taltz[®]. Prescribing Information. Lilly USA, LLC, <u>https://taltz.lilly.com/hcp/moa-ill7a-igg4</u>. Acronyms: IgG4, immunoglobulin G4; K_D, dissociation constant; pM, picomolar

Ongoing Novartis Phase 2b Multicenter Platform Study Offers Additional Clinical Evidence of B Cell Targeting Benefit in HS



Presented at the American Academy of Dermatology Annual Meeting; March 8–12, 2024; San Diego, CA.



*Study started in February 2019 and is currently ongoing.

BAFF-R, B-cell activating factor of the tumor necrosis alpha family receptor; b.i.d., twice daily; BTKi, Bruton's tyrosine kinase inhibitor; CD, cluster of differentiation; D, day; EOS, end of study; HS, hidradenitis suppurativa; IL, interleukin; LTA4H, leukotriene A4 hydrolase; MoA, mechanism of action; PEA, primary endpoint analysis; R, randomization; s.c., subcutaneous; W, week. Clinicaltrials.gov NCT03827798. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT03827798 (Accessed 6 Mar 2024).

©2024 Zura Bio Ltd. **29**


Novartis' Interim Results Presented at '24 AAD: BTKi PBO-Adjusted Delta Aligns with Approved and In-Development Agents



tibulizumab | ZB-106

Presented at the American Academy of Dermatology Annual Meeting; March 8–12, 2024; San Diego, CA.

 The primary endpoint of this study was met for both doses of remibrutinib; patients treated with remibrutinib reported a greater rate of sHiSCR* at Week 16 compared with placebo



*The sHiSCR is defined as a ≥50% reduction in the abscess and inflammatory nodule count and no increase in draining tunnels compared with baseline. †Difference refers to the difference between remibrutinib (either dose) and pooled placebo at Week 16. ‡Bayesian posterior probability of remibrutinib (either dose) being better than pooled placebo. CI, confidence interval; HiSCR, hidradenitis suppurativa clinical response; n, total number of patients with response; N, total number of patients in each treatment arm; NRI, non-responder imputation; sHiSCR, simplified hidradenitis suppurativa clinical response.


©2024 Zura Bio Ltd. **30**




tibulizumab | ZB-106

KEY INCLUSION CRITERIA

- Moderate to Severe HS
- Hurley Stage II/III
- Total abscess and inflammatory nodule count (AN) ≥ 5
- Up to 30% TNF inadequate responders





(*) Study design is subject to change.

Sources: Zura Internal Planning

Acronyms: DLQI, dermatology life quality index; HiSCR, Hidradenitis Suppurativa Clinical Response; HS, hidradenitis suppurativa; IHS4, international hidradenitis suppurativa severity score system; PD, pharmacodynamic; PGA, physician's global assessment; PK, pharmacokinetic; R, randomization

Tibulizumab Summary



The Phase 2 development programs for systemic sclerosis and hidradenitis suppurativa are progressing

The strategy follows validated pathways with the potential for improved outcomes, supported by related mechanism-of-action data from IL-17 and BAFF/B-cell depletion therapies

We believe tibulizumab is positioned as a potential first-in-class dual-pathway biologic

The next 6 to 12 months offer significant growth opportunities, with multiple key milestones anticipated

crebankitug

ZB-168 Anti-IL-7Rα + TSLP

Crebankitug is a high-affinity, fully human monoclonal antibody that neutralizes the IL-7 receptor alpha (IL- $7R\alpha$) chain, potentially blocking the immune pathways of IL-7 and thymic stromal lymphopoietin (TSLP).

Crebankitug



crebankitug | ZB-168

Crebankitug, a fully human IL-7Rα antibody

Well tolerated in Phase 1 and Phase 1b studies

- Originally developed by Pfizer
- IL-7Rα inhibition has potential to inhibit two critical immune pathways (IL-7 and TSLP)
- Potential applicability in broad range of T-cell mediated diseases and atopic diseases.

- >90 participants dosed with crebankitug
 - Adverse events generally mild and not treatment-related.

Phase 1b data demonstrate clear evidence of impact on key T-cell compartments

- Only anti-IL7R program that has reported safety, PK, and PD data in participants with an auto immune disease (not just healthy volunteers)
- Potentially clinically relevant changes observed in memory T-cell counts and T_{reg}: T_{memory} ratios.

Actively assessing Phase 2 strategy

- Ongoing internal planning for indications in areas with unmet needs.
- Will be evaluating Phase 2 IL-7Rα and TSLP competitor data readouts.


creban- creating balance ki- cytokine or cytokine receptor tug- unmodified immunoglobulin

Crebankitug: A Multi-Functional Antibody That Blocks Signaling via IL-7 and TSLP Pathways



crebankitug | ZB-168

IL-7R α is a key receptor in immune regulation, central to the signaling of cytokines **IL-7** and **TSLP**



Positioning crebankitug for potential applications in diverse immune-related and autoimmune conditions

©2024 Zura Bio Ltd. **35**


Both TSLP and IL-7 Have a Role in Activating Th1, Th2, and **Th17-Driven Inflammation**



crebankitug | ZB-168

IL-7 PATHWAY

- IL-7 is a growth factor that binds to the heterodimeric receptor of IL-7R:yC and is critical for the survival. development and homeostasis of central and effector memory T cells ⁴
- Due to the high expression of IL-7R on T_{eff} compared to T_{rea}, inhibition results in a 20-fold greater activity in reducing T_{eff}, leading to an increase in T_{reg}:T_{eff} ratio ^{5, 6}




Sources: ¹ Ebina-Shibuya, R. and Warren Leonard. Nature Reviews Immunology, doi:10.1038/s41577-022-00735-y; ² Marone, G., et al. Expert Opinion on Investigational Drugs, doi:10.1080/13543784.2019.1672657; ³ Menzies-Gow, A., et al. Respiratory Research, doi:10.1186/s12931-020-01505-x; ⁴ Chen, 2021. Frontiers Immunol, 5. Herold, K., et al. JCI Insight, doi:10.1172/jci.insight.126054; graphic created in BioRender; 5 Martin, M.and Badovinac P. Frontiers in Immunology, doi:10.3389/fimmu.2018.02692; 6 Waickman, A., et al. iScience, doi:10.1016/j.isci.2020.101421; ⁷ Marković, I. and Savvides S. Frontiers in Immunology, doi:10.3389/fimmu.2020.01557.

TSLP PATHWAY

- Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine primarily expressed in the lungs, skin and gastrointestinal tract ¹
- TSLP is released from the epithelium by disease amplifying Th2 immune response, including the production of IL-4, -5, -9 and -13.1
- TSLP inhibition is clinically validated in severe asthma and has shown positive therapeutic benefit in additional Th2 driven diseases 2,3


Crebankitug Is the Only mAb to Potently Inhibit Both IL-7R and TSLP **v** zurabio



Inhibition of TSLP stimulated CCL17 secretion from human monocytes

World Allergy Congress Poster, Dec 2023

% inhibition of TSLP stimulated CCL17 secretion from human monocytes




Source: ¹ Zura Internal Data; ² Herold, Kevan C., et al. JCI Insight, doi:10.1172/jci.insight.126054; ³ Numazaki, Mako, et al. Journal of Pharmacology and Experimental Therapeutics, doi:10.1124/jpet.121.000686; ⁴ Yamniuk, Aaron P., et al. Antibodies against II-7r Alpha Subunit and Uses Thereof. 18 May 2021. Acronyms: CCL17, C-C motif chemokine ligand 17; IL, interleukin; mAb, monoclonal antibody; TSLP, thymic stromal lymphopoietin


Dual Inhibition of Th1 and Th2 May Offer Broader or Deeper Levels of Response in Atopic Dermatitis

crebankitug | ZB-168

zurabio

- TSLP and IL-25 activate Th2 cells, which are crucial in the early stages of atopic dermatitis.
- As the condition progresses, the influence of Th2 decreases, while Th1 and Th17 responses become more prominent.
- Targeting both Th2 and Th1 pathways may offer broader and more effective treatment options.






Crebankitug Provides Optionality for Clinically Validated Development or Novel Indications



crebankitug | ZB-168



Sources: ¹ClinicalTrials.gov database, Company Presentations; ²Zura Internal Planning Acronyms: GI, gastrointestinal; IL, interleukin; PoC, proof-of-concept; TSLP, thymic stromal lymphopoietin

Crebankitug Summary



Crebankitug targets immune-related and autoimmune conditions linked to IL-7R or TSLP signaling

In three Phase I and Ib studies involving 93 participants, crebankitug was well-tolerated, with most adverse events being mild and unrelated to the treatment

Only anti-IL-7Rα program with clinical data showing impact on key T-cell subpopulations, indicating potential for broad T-cell mediated and atopic diseases

Advancing indication planning and monitoring IL-7R and TSLP therapies to support Phase 2 strategy


torudokimab

ZB-880 Anti-IL-33

> Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent (e.g., RAGE) inflammation.



torudokimab | ZB-880



Sources: ¹ Cohen, S., et al. Nature Communications, doi:10.1038/ncomms9327; ² Clinicaltrials.Gov, clinicaltrials.gov/ct2/show/NCT03913260. Accessed 26 Aug. 2024; Clinicaltrials.Gov, clinicaltrials.gov/ct2/show/NCT0381191. Accessed 26 Aug. 2024; Section 6.1, DSUR for period 23-Sep-2019 to 22-Sep-2020; ³ Laquer, V., et al. British Journal of Dermatology, doi:10.1111/bjd.21631. ⁴ Okragly, A., et al. Journal of Inflammation Research, doi:10.2147/jir.s320287. ⁵ Wechsler, M., et al. New England Journal of Medicine, doi:10.1056/nejmoa2024257.

©2024 Zura Bio Ltd. **42**



torudokimab | ZB-880


IL-33 is a member of the IL-1 cytokine family that is constitutively expressed in structural and lining cells including fibroblasts, endothelial, and epithelial cells of skin, gastrointestinal tract, and lungs ¹	IL-33 is released from the epithelium by disease exacerbating environmental factors and is an important amplifier of innate inflammation during exacerbations ²	allergens viruses LL25 TSLP			
Polymorphisms in IL-33 and ST2 are associated with increased eosinophil production as well as respiratory diseases such as COPD and severe asthma	IL-33 inhibition clinically validated in severe asthma, COPD ³ , and subsets of other epithelial disorders ⁴	PGD ₂ Histamin proteases DC LC2 IL13 IL5			
Pre-clinical data demonstrates superior activity of torudokimab compared with etokimab and itepekimab suggesting the potential for best-in- class activity ⁵	Emerging biology suggests expanding opportunity for IL-33 in fibrotic and autoimmune conditions ⁶	Amphiregulin TCR GM-CSF IL13 IL9 IL9 IL13 IL4 IL5 IL1 IL13 IL4 IL5 IL13 IL4 IL5 IL13 IL4 IL5 IL13 IL4 IL5 IL13 IL13 IL4 IL5 IL13 IL13 IL13 IL13 IL4 IL5 IL13 IL5 IL13 IL13 IL5 IL13 IL5 IL13 IL5 IL13 IL5 IL13 IL5 IL13 IL5 IL13 IL5 IL5 IL13 IL5 IL5 IL5 IL5 IL5 IL5 IL5 IL5			

Sources: ¹ Chan, B., et al. Frontiers in Immunology, doi:10.3389/fimmu.2019.00364; ² Cayrol, C. and Girard, J.P. Cytokine, doi:10.1016/j.cyto.2022.155891. ³ Gudbjartsson, D., et al. Nature Genetics, doi:10.1038/ng.323; Ketelaar, M., et al. Journal of Allergy and Clinical Immunology, doi:10.1016/j.jaci.2020.04.051; ⁴ Singh, D. The Lancet Respiratory Medicine, doi:10.1016/s2213-2600(22)00005-4; Wechsler, M., et al. New England Journal of Medicine, doi:10.1056/nejmoa2024257; Chen, Yi-Ling, et al. Science Translational Medicine, doi:10.1126/scitransImed.aax2945; ⁵ Zura Internal data;
 ⁶ Pei, C., et al. Immunology, doi:10.1111/imm.12174; Kurimoto, M., et al. Frontiers in Physiology, doi:10.3389/fphys.2021.781012; Dong, Y., et al. Frontiers in Medicine, doi:10.3389/fmed.2021.739489.

Torudokimab Has Potential for "Best-in-Class" Activity 🛛 💎 zurabio

torudokimab | ZB-880

Torudokimab was 2.9 and 5.5-fold more potent than etokimab and itepekimab, respectively, inhibiting IL-33-induced GM-CSF production by human mast cells



Antibody	k _{on} (M⁻¹s⁻¹)	k _{off} (s⁻¹)	k _d (pM)	Torudokimab Potency
torudokimab (LY3375880)	1.7 × 10 ⁶	6.7 × 10 ⁻⁵	39	
etokimab (AnaptysBio)	9.4 x 10 ⁵	1.2 x 10 ⁻⁴	112	2.9x
itepekimab (Regeneron)	7.6 x 10 ⁵	1.6 x 10 ⁻⁴	215	5.5x

Corporate Update

Team and Cash Runway

Zura's Leadership: Driving Innovation in I&I





Acronyms: I&I, inflammation and immunology; SAB, scientific advisory board

Key milestones^{*} expected through 2026

	\longrightarrow	Cash runway expected through 2027				
MILESTONE LEGEND:		2H-2024	2025	2026		
▲ External Catalyst		Select CRO	Phase 2 study recruitment	SSc Topline Data		
tibulizumab	SSc study	 Obtain IND from US FDA Initiate a Phase 2 study in SSc 		Pending data outcomes, Phase 3 $ ightarrow ightarrow ightarrow$		
	HS study	Select CRO	 Obtain IND from US FDA Initiate a Phase 2 study in HS 	□ HS Topline Data Pending data outcomes, Phase $3 \rightarrow \rightarrow \rightarrow$		
crebankitug	Indication Planning Ongoing	 Complete internal indication planning 4Q-2024: Phase 2a Topline Data bempikibart in AA, Q32 Bio 4Q-2024: Phase 2 Topline Data bempikibart in AD, Q32 Bio 3Q-2024: Phase 3 Topline Data tezepelumab in Asthma (reducing corticosteroid), Amgen 	Select indication for future development* Indication selection to guide future	ture crebankitug milestones → → →		
torudokimab	Indication Evaluation On-going		 2Q-2025: Phase 3 Study Complete <u>itepekimab in COPD, Sanofi</u> 2Q-2025: Phase 3 Topline Data <u>astegolimab in COPD, Roche</u> Complete internal indication planning 	ture torudokimab milestones → → →		

The timing of regulatory and clinical trial milestones are subject to change and additional discussion with the FDA

Sources: Internal Zura Planning

Acronyms: AA, alopecia areata; AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; CRO, contract research organization; HS, hidradenitis suppurativa; SSc, systemic sclerosis; US FDA, United States Food & Drug Administration

💎 zurabio





Nasdaq ticker: ZURA

April 2024 Photo courtesy of ©Nasdaq, Inc. **Our mission:** Driving scientific breakthroughs by turning drug discoveries into transformative, life-saving treatments.

Tibulizumab shows best-in-class potential: Introducing a tetravalent antibody therapy designed to target and potentially treat autoimmune diseases.

Promising pipeline for value creation: Integrating validated biological pathways into multifunctional antibody assets to potentially improve therapeutic outcomes.

Upcoming external catalysts: Anticipating near-term developments that could further expand the pipeline's potential.

Proven leadership: Experienced team with a track record of contributing to over \$8 billion in mergers and acquisitions in the past three years.

Strong financial position: With approximately \$188 million¹ in cash, cash equivalents, and investments, we are funded to support our planned operations through 2027. The 3Q 2024 IPO warrant exchange has streamlined our share structure, and additional financing through ATM options remains available for future needs. As of August 29, 2024, we have 63,774,183 Class A Ordinary Shares outstanding².